Drug intelligence / Profile preview

LY01024

Development stage: Phase 2
Lead developer: Luye Pharma
Modality: Small Molecules
Administration: Oral

Overview

LY01024 (also known as LPM-6690176) is an orally administered investigational antineoplastic agent developed for the treatment of solid tumors, including inoperable, unresectable, metastatic, and late-stage disease. The specific mechanism of action is currently undefined, and publicly available data does not detail molecular targets or pathways. LY01024 is classified as a new molecular entity and, as of March 2024, is undergoing Phase I clinical trials for solid tumors in China.

Brand names: LY01024LY-01024LY 01024
Other names: LPM-6690176LPM6690176LPM 6690176

Targets

SOS1 (Son of sevenless homolog 1)

Beyond the preview

Go deeper on LY01024.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY01024.

Explore the full profile